Process for preparing beta 3 agonists and intermediates
The application is directed to efficient and economical processes as described in more detail below for the preparation of the beta 3 agonists of the formula of I-7 and intermediate compounds that can be used for making these agonists. The present disclosure relates to a process for making beta-3 agonists and intermediates using ketoreductase (KRED) biocatalyst enzymes and methods of using the biocatalysts.
1. A crystalline form of the HCl salt of Compound I-5(b), wherein Compound I-5(b) has the chemical structure:
and wherein the crystalline form is characterized by an XRPD pattern having 2θ peaks at about 8.6°, 13.5°, and 16.7° 20.9°, and 22.7°.
2. The crystalline form of claim 1 , wherein the crystalline form is characterized by an XRPD pattern having 2θ peaks at about 8.6°, 12.9°, 13.5°, 16.7°, 20.9°, 22.7°, and 24.4°.
3. The crystalline form of claim 1 , wherein the crystalline form is characterized by an XRPD pattern having 2θ peaks at about 4.2°, 8.6°, 12.9°, 13.5°, 16.7°, 20.9°, 22.7°, 24.4°, 24.7°, and 28.2°.
4. The crystalline form of claim 1 , wherein the crystalline form is characterized by an XRPD pattern as shown in FIG. 1 .
5. The crystalline form of claim 1 , wherein the crystalline form is characterized by an XRPD pattern having the following reflections with the d-spacing
Position [°2 Theta]
d-spacing [Å]
4.2174
20.95196
8.5827
10.3028
12.9282
6.84784
13.5177
6.55051
16.65
5.32461
20.9425
4.24193
22.6974
3.91777
24.363
3.65356
24.6986
3.60468
28.1911
3.16555.